
Passage Bio PASG
€ 6.99
-0.55%
Geschäftsbericht 2025
hinzugefügt 03.03.2026
Passage Bio Langfristiger Schuldenstrom 2011-2026 | PASG
Langfristiger Schuldenstrom Jährlich Passage Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.57 M | 3.69 M | 3.37 M | 3.28 M | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 3.69 M | 3.28 M | 3.48 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Amgen
AMGN
|
135 M | $ 345.82 | 1.71 % | $ 186 B | ||
|
Amneal Pharmaceuticals
AMRX
|
6.76 M | $ 12.61 | 2.35 % | $ 3.95 B | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | ||
|
argenx SE
ARGX
|
10.8 M | $ 776.24 | 1.41 % | $ 25 B | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 24.35 | 4.64 % | $ 3.1 B | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.44 | 5.51 % | $ 383 M | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.85 | 2.39 % | $ 9.26 B | ||
|
CymaBay Therapeutics
CBAY
|
7 K | - | - | $ 3.45 B | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Aytu BioScience
AYTU
|
137 K | $ 2.74 | 6.42 % | $ 17.2 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 91.34 | 1.92 % | $ 27.2 B | ||
|
Avid Bioservices
CDMO
|
1.35 M | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
1.38 M | - | - | $ 1.41 B | ||
|
Cabaletta Bio
CABA
|
3.46 M | $ 3.09 | 0.65 % | $ 310 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.07 | 1.32 % | $ 6.68 B | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Concert Pharmaceuticals
CNCE
|
1.16 M | - | - | $ 401 M | ||
|
Cerus Corporation
CERS
|
2.9 M | $ 1.94 | 5.43 % | $ 370 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
CTI BioPharma Corp.
CTIC
|
781 K | - | - | $ 1.2 B | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Cellectar Biosciences
CLRB
|
100 K | $ 2.92 | 6.18 % | $ 7.62 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
3.5 M | - | - | $ 2.18 B | ||
|
Dynavax Technologies Corporation
DVAX
|
4.18 M | - | - | $ 2.02 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Coherus BioSciences
CHRS
|
1.83 M | $ 1.68 | 0.6 % | $ 197 M |